Poolbeg Pharma has completed an Initial Public Offering on AIM
Poolbeg Pharma Plc has raised funds to develop the company.
Poolbeg Pharma is a clinical-stage, infectious disease pharmaceutical company with a capital light clinical model which aims to develop multiple products faster and more cost-effectively than the conventional biotech model, aspiring to become a one-stop shop for Big Pharma seeking mid-stage products to license or acquire. The company was formed from a spin-out of assets from Open Orphan Plc and is headquartered in London, UK.
Oaklins Cavendish’s sister firm finnCap, based in the UK, in its role as IPO advisor, assisted Poolbeg Pharma’s management team and shareholders all the way from the start to the successful completion of the IPO. During this process, the team initiated and advised on many aspects, including, among others, securing commitments from investors, asset spin out deal structuring, EIS eligibility, and the IPO pricing and sizing.
Talk to the deal team
Managing DirectorLondon, United Kingdom
PartnerLondon, United Kingdom
Bigtincan (ASX:BTH) has raised capital to fund the acquisition of Brainshark Inc.
Bigtincan Holdings Limited (ASX:BTH) has raised US$98.6 via a placement and underwritten accelerated non-renounceable entitlement offer.Learn more
Alice Queen (ASX:AQX) has raised funds via an institutional placement
Alice Queen Limited (ASX:AQX) has completed a fundraising. The funds will be used to complete the Horn Island Scoping Study, accelerate exploration activities at Horn Island and support working capital. The placement was significantly oversubscribed and strongly supported by a major shareholder, as well as several existing shareholders and new institutional and sophisticated investors.Learn more
ScreenPoint Medical has raised US$28 million in a Series C investment round led by Insight Partners
Netherlands-based ScreenPoint Medical, an AI technology company that develops advanced image recognition and machine learning software to improve early detection of breast cancer, has raised US$28 million (€24 million) in a Series C funding round led by New York-based global venture capital and private equity firm Insight Partners to further develop its technology and accelerate commercial growth of the company’s Transpara AI breast care software.Learn more